# TUXEDO-1 (NCT04752059)

> Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04752059
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Medical University of Vienna
- Conditions: Breast Cancer Stage IV
- Interventions: Trastuzumab deruxtecan
- Enrollment: 15
- Primary outcome: Reponse rate of brain metastases to trastuzumab-deruxtecan

## Commentary we found

- Podcasts: 12
- YouTube: 11
- X threads: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tuxedo-1-nct04752059

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04752059", "email": "<work email>"}; the inbox owner confirms by the emailed link.